SG129998A1 - Compounds possessing neuronal activity - Google Patents

Compounds possessing neuronal activity

Info

Publication number
SG129998A1
SG129998A1 SG200201262-3A SG2002012623A SG129998A1 SG 129998 A1 SG129998 A1 SG 129998A1 SG 2002012623 A SG2002012623 A SG 2002012623A SG 129998 A1 SG129998 A1 SG 129998A1
Authority
SG
Singapore
Prior art keywords
neuronal activity
compounds possessing
possessing neuronal
compounds
activity
Prior art date
Application number
SG200201262-3A
Other languages
English (en)
Inventor
Patricia Mccaffrey
Perry M Novak
Michael Mullican
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/085,441 external-priority patent/US6268384B1/en
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SG129998A1 publication Critical patent/SG129998A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG200201262-3A 1997-08-29 1998-08-27 Compounds possessing neuronal activity SG129998A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92083897A 1997-08-29 1997-08-29
US09/085,441 US6268384B1 (en) 1997-08-29 1998-05-27 Compounds possessing neuronal activity

Publications (1)

Publication Number Publication Date
SG129998A1 true SG129998A1 (en) 2007-03-20

Family

ID=26772724

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200201262-3A SG129998A1 (en) 1997-08-29 1998-08-27 Compounds possessing neuronal activity

Country Status (17)

Country Link
US (1) US7109215B2 (fr)
EP (1) EP1007521A1 (fr)
JP (1) JP2001514177A (fr)
CN (1) CN100436447C (fr)
AU (1) AU766579B2 (fr)
BR (1) BR9811923A (fr)
CA (1) CA2300134A1 (fr)
ID (1) ID23675A (fr)
IL (1) IL134536A0 (fr)
IN (1) IN191127B (fr)
IS (1) IS5379A (fr)
NO (1) NO321790B1 (fr)
NZ (1) NZ502820A (fr)
PL (1) PL195273B1 (fr)
SG (1) SG129998A1 (fr)
TW (1) TW570919B (fr)
WO (1) WO1999010340A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
WO1999062880A1 (fr) * 1998-06-03 1999-12-09 Gpi Nil Holdings, Inc. Sulfonamides a liaison n d'acides carboxyliques n-heterocycliques ou d'isosteres d'acide carboxylique
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6300341B1 (en) * 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
EP1196387A1 (fr) 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated Derives d'acides amines azoiques pour le traitement des maladies neurologiques
WO2001002368A1 (fr) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Derives n-heterocycliques possedant une activite neuronale
EP1196385A1 (fr) * 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated Derives de beta-aminoacide destines au traitement de maladies neurologiques
WO2001009097A1 (fr) * 1999-07-30 2001-02-08 Vertex Pharmaceuticals Incorporated Derives amines cycliques convenant au traitement d'affections neurologiques
MXPA02001095A (es) * 1999-07-30 2002-08-20 Vertex Pharma Derivados de amina ciclicos y aciclicos.
WO2001012622A1 (fr) * 1999-08-18 2001-02-22 Schering Aktiengesellschaft Derives de piperidine et de pyrrolidine ayant une activite neuronale
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
EP1244670B1 (fr) 1999-12-21 2006-03-08 MGI GP, Inc. Composes a base de derives d'hydanto ne, compositions pharmaceutiques, et modes d'utilisation
JP2002068973A (ja) * 2000-06-16 2002-03-08 Meiji Milk Prod Co Ltd 幹細胞分化誘導促進剤
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
MXPA05003471A (es) * 2002-10-03 2005-07-01 Vertex Pharma Derivados de piperazina y piperadina para el tratamiento de enfermedades neurologicas.
WO2005033068A1 (fr) * 2003-10-06 2005-04-14 Oy Juvantia Pharma Ltd Recepteur 1 et/ou 4 de somatostatine, agonistes et antagonistes selectifs
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
CA2637707A1 (fr) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Procedes de traitement de l'obesite par administration d'un antagoniste trkb
KR20090091181A (ko) * 2006-12-20 2009-08-26 리나트 뉴로사이언스 코퍼레이션 자가면역 장애의 치료를 위한 티로신 수용체 키나아제 ｂ 작용제
US9152929B2 (en) 2013-01-23 2015-10-06 Splunk Inc. Real time display of statistics and values for selected regular expressions
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021313A2 (fr) * 1991-05-24 1992-12-10 Vertex Pharmaceuticals Incorporated Nouveaux composes immunosuppresseurs
WO1995026337A1 (fr) * 1994-03-25 1995-10-05 Vertex Pharmaceuticals Incorporated Nouveaux carbamates et urees utilises pour modifier la resistance multi-medicamenteuse
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792555A (en) * 1987-03-20 1988-12-20 American Home Products Corporation Phospholipase A2 inhibitors
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5686469A (en) * 1993-02-09 1997-11-11 Miles Inc. Aminomethylene derivaties as immunosuppressants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021313A2 (fr) * 1991-05-24 1992-12-10 Vertex Pharmaceuticals Incorporated Nouveaux composes immunosuppresseurs
WO1995026337A1 (fr) * 1994-03-25 1995-10-05 Vertex Pharmaceuticals Incorporated Nouveaux carbamates et urees utilises pour modifier la resistance multi-medicamenteuse
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds

Also Published As

Publication number Publication date
TW570919B (en) 2004-01-11
IS5379A (is) 2000-02-18
JP2001514177A (ja) 2001-09-11
BR9811923A (pt) 2000-08-15
NZ502820A (en) 2002-10-25
ID23675A (id) 2000-05-11
IN191127B (fr) 2003-09-27
NO20000953L (no) 2000-05-02
AU8923698A (en) 1999-03-16
NO20000953D0 (no) 2000-02-25
PL195273B1 (pl) 2007-08-31
WO1999010340A1 (fr) 1999-03-04
NO321790B1 (no) 2006-07-03
CN100436447C (zh) 2008-11-26
IL134536A0 (en) 2001-04-30
AU766579B2 (en) 2003-10-16
PL338791A1 (en) 2000-11-20
US7109215B2 (en) 2006-09-19
CA2300134A1 (fr) 1999-03-04
EP1007521A1 (fr) 2000-06-14
US20020013351A1 (en) 2002-01-31
CN1271354A (zh) 2000-10-25

Similar Documents

Publication Publication Date Title
ZA987478B (en) Compounds possessing neuronal activity
PL338791A1 (en) Compounds exhibiting neuronic activity
GB9710569D0 (en) Compounds
GB9708694D0 (en) Compounds
GB9708805D0 (en) Compounds
GB9726365D0 (en) Compounds
GB9709303D0 (en) Compounds
GB9704522D0 (en) Compounds
GB9723247D0 (en) Azaboroxine compounds
GB9702978D0 (en) Compounds
HK1028601A (en) Compounds possessing neuronal activity
GB9725138D0 (en) Thiophenesulfonamide compounds
AU132782S (en) Aviary
GB9704551D0 (en) Compounds
GB9708937D0 (en) Compounds
GB9716235D0 (en) Compounds
GB9705652D0 (en) Compounds
GB9719191D0 (en) Compounds
GB9708936D0 (en) Compounds
GB9707443D0 (en) Compounds
GB9727054D0 (en) Compounds
GB9720107D0 (en) Compounds
GB9705188D0 (en) Compounds
GB9708071D0 (en) Compounds
GB9705189D0 (en) Compounds